What is the treatment for pericarditis with a depressed PR (P-R) interval?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Pericarditis with Depressed PR Interval

The presence of a depressed PR interval on ECG is a typical finding in acute pericarditis and does not alter the standard treatment approach—first-line therapy remains high-dose NSAIDs (aspirin 750-1000 mg every 8 hours or ibuprofen 600 mg every 8 hours) combined with colchicine for 3 months. 1, 2

Understanding the PR Depression

The depressed PR segment is a characteristic ECG finding in acute pericarditis, typically appearing in Stage I alongside ST elevation. 1 This finding reflects:

  • Atrial involvement in the inflammatory process, distinguishing pericarditis from myocardial infarction 1
  • PR depression is most prominent in leads I, II, aVL, aVF, and V3-V6, while PR elevation occurs in aVR 1
  • This ECG pattern does not indicate worse prognosis or require treatment modification 1

First-Line Treatment Protocol

NSAIDs with Gastroprotection

Aspirin or ibuprofen are Class I, Level A recommendations as initial therapy: 1, 2

  • Aspirin: 750-1000 mg every 8 hours for 1-2 weeks 1, 2
  • Ibuprofen: 600 mg every 8 hours for 1-2 weeks (preferred for better coronary flow and fewer side effects) 1
  • Mandatory gastroprotection must be provided 1, 2
  • Avoid indomethacin in elderly patients due to coronary flow reduction 1

Colchicine as Mandatory Adjunct

Colchicine is a Class I, Level A recommendation to be added to NSAIDs, not used as monotherapy: 1, 2

  • Weight-adjusted dosing: 0.5 mg once daily if <70 kg, or 0.5 mg twice daily if ≥70 kg 1, 2
  • Duration: 3 months minimum 1, 2
  • Reduces recurrence risk from 37.5% to 16.7% (absolute risk reduction 20.8%) 3

Treatment Duration and Tapering

Continue therapy until symptoms resolve AND CRP normalizes: 1, 2

  • NSAIDs: Typically 1-2 weeks, then taper by 250-500 mg (aspirin) or 200-400 mg (ibuprofen) every 1-2 weeks 1, 2
  • Monitor CRP levels to guide treatment length and assess response 1, 2
  • Premature tapering (within 1 month) increases recurrence risk 4

Second-Line Treatment (Only After First-Line Failure)

Corticosteroids are Class IIa, Level C recommendations and should be avoided as initial therapy due to increased risk of chronicity and recurrence: 1, 2

Indications for Corticosteroids

  • Contraindication or failure of aspirin/NSAIDs and colchicine 1, 2
  • Autoimmune disease or uremic pericarditis 1
  • After infectious causes excluded 1
  • Patients on anticoagulation where NSAIDs pose high bleeding risk 5

Corticosteroid Dosing

Use low to moderate doses only: 1, 2, 5

  • Prednisone 0.2-0.5 mg/kg/day (NOT 1.0 mg/kg/day) 1, 2, 5
  • Always combine with colchicine when using corticosteroids 1, 5
  • Slow tapering schedule based on initial dose: 5
    • 50 mg: Decrease by 10 mg every 1-2 weeks

    • 50-25 mg: Decrease by 5-10 mg every 1-2 weeks
    • 25-15 mg: Decrease by 2.5 mg every 2-4 weeks
    • <15 mg: Decrease by 1.25-2.5 mg every 2-6 weeks

Risk Stratification and Monitoring

Hospitalization is warranted to determine etiology and observe for tamponade: 1

  • Low-risk cases: Outpatient management with NSAIDs and colchicine 1, 2
  • Monitor response after 1 week using symptoms and CRP 1, 5
  • Exercise restriction until symptoms resolve and CRP, ECG, and echocardiogram normalize 1, 2
  • Athletes require 3 months minimum restriction from competitive sports 1, 2

Critical Pitfalls to Avoid

Inadequate treatment of the first episode is the most common cause of recurrence: 2

  • Never use corticosteroids first-line unless specific contraindications exist—they increase recurrence risk from 15-30% to 50% 2, 6, 3
  • Do not taper before CRP normalizes—this promotes recurrence 1, 2
  • Do not omit colchicine—it is essential for preventing recurrence 1, 2, 3
  • Ensure full 3-month colchicine course—shorter durations increase recurrence 1, 2

Refractory Cases

For patients failing NSAIDs, colchicine, and corticosteroids: 5, 6, 3, 4

  • IL-1 blockers (anakinra, rilonacept, goflikicept) as third-line therapy 5, 6, 3, 4
  • Immunomodulatory agents (azathioprine, IVIG) for select cases 5, 6
  • Pericardiectomy only as last resort after all medical therapies fail 5, 6, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Initial Treatment for Pericarditis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Pericarditis in Patients Taking Anticoagulants

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Recurrent pericarditis.

La Revue de medecine interne, 2017

Research

Pericarditis and pericardial effusion: management update.

Current treatment options in cardiovascular medicine, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.